Cart
sales@molnova.com
BPTES
CAS No. 314045-39-1
BPTES( BPTES )
Catalog No. M18414 CAS No. 314045-39-1
BPTES(IC50 of 0.16 μM) is an effective and specific GlutamiN/Ase GLS1 (KGA) inhibitor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 40 | In Stock |
|
| 5MG | 57 | In Stock |
|
| 10MG | 73 | In Stock |
|
| 25MG | 138 | In Stock |
|
| 50MG | 206 | In Stock |
|
| 100MG | 308 | In Stock |
|
| 200MG | 447 | In Stock |
|
| 500MG | 732 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameBPTES
-
NoteResearch use only, not for human use.
-
Brief DescriptionBPTES(IC50 of 0.16 μM) is an effective and specific GlutamiN/Ase GLS1 (KGA) inhibitor.
-
DescriptionBPTES is a selective inhibitor of Glutaminase GLS1 (KGA), which is found in the kidney and brain, and is positively regulated by myc and strongly expressed in many tumors and tumor cell lines. BPTES has a K(i) of approx. 3 microM. BPTES inhibits the allosteric activation caused by phosphate binding and promotes the formation of an inactive complex.
-
In Vitro——
-
In Vivo——
-
SynonymsBPTES
-
PathwayChromatin/Epigenetic
-
TargetSirtuin
-
RecptorGlutaminase GLS1 (KGA)
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number314045-39-1
-
Formula Weight524.68
-
Molecular FormulaC24H24N6O2S3
-
Purity>98% (HPLC)
-
SolubilityDMSO : 50 mg/mL 95.30 mM;H2O : < 0.1 mg/mL
-
SMILESO=C(Cc1ccccc1)Nc1nnc(s1)CCSCCc1sc(nn1)NC(=O)Cc1ccccc1
-
Chemical NameN,N'-((thiobis(ethane-2,1-diyl))bis(1,3,4-thiadiazole-5,2-diyl))bis(2-phenylacetamide)
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Le A., et al. Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. Cell Metab. 2012 Jan 4;15(1):110-21.
molnova catalog
related products
-
Pristimerin
Pristimerin has anticancer activity, treatment with Pristimerin may be a potential strategy for the suppression of hypoxia-induced metastasis through the reversal of hypoxia-induced stem cell characteristics and EMT in cancer cells.
-
JH-T4
JH-T4 is a potent small molecule SIRT2 inhibitor with IC50 of 0.3 uM.
-
JGB1741
JGB1741 is a potent and selective inhibitor of SIRT1 with an IC50 of 15 μM. JGB1741 modulates Bax/Bcl2 ratio, cytochrome c release and PARP cleavage and increases the acetylated p53 levels leading to p53-mediated apoptosis. JGB1741 can be used in studies about breast cancer.
